You might also like
Merck & Co., Inc. (Merck) is a global healthcare company that operates through two main segments: Pharmaceutical and Animal Health. The company develops and sells human health pharmaceutical and vaccine products, primarily by prescription, for the treatment of human disorders, as well as veterinary pharmaceutical and vaccine products for livestock and companion animals . Merck's revenue growth is driven by strong performance in oncology, vaccines, and animal health, with significant contributions from products like Keytruda and Gardasil/Gardasil 9 .
- Pharmaceutical - Develops and sells human health pharmaceutical and vaccine products, primarily by prescription, for the treatment of human disorders. Key products include Keytruda and Gardasil/Gardasil 9, which are major contributors to revenue growth.
- Animal Health - Focuses on veterinary pharmaceutical and vaccine products, as well as health management solutions for livestock and companion animals. Includes digitally connected identification, traceability, and monitoring products.
- Livestock Products - Provides pharmaceutical and vaccine products for livestock health management.
- Companion Animal Products - Offers pharmaceutical and vaccine products for the health of companion animals.
- "You've mentioned that GARDASIL shipments to your partner in China have decreased and that inventory at Zhifei remains above historical levels ; what specific strategies are you implementing to address the demand challenges in China, and how confident are you in achieving your goal of over $11 billion in GARDASIL sales by 2030 ?"
- "Operating expenses have increased significantly due to strategic investments and charges related to acquisitions like EyeBio and Curon ; can you provide more detail on how these investments will contribute to your long-term growth and justify the increased expenditure ?"
- "Given the decline in GARDASIL sales in China and the anticipated similar level of shipments in the fourth quarter , how do you plan to mitigate the impact on your overall revenue growth and what other markets are you focusing on to offset this shortfall ?"
- "You have stated that your Phase III pipeline has nearly tripled over the past three years to more than 20 unique assets ; can you elaborate on the timing of these assets reaching the market and how they will contribute to revenue in the face of upcoming patent expirations, especially for KEYTRUDA ?"
- "In terms of capital allocation, you mentioned you have capacity to do 'pretty much anything of any size' but are focusing on deals in the $1 billion to $15 billion range ; with the increasing competition in the obesity market, why are you limiting your deal size, and how will this approach enable you to remain competitive in high-growth therapeutic areas ?"
Competitors mentioned in the company's latest 10K filing.
- AbbVie Inc. - Part of the composite peer group of major U.S. and European-based pharmaceutical companies .
- Amgen Inc. - Part of the composite peer group of major U.S. and European-based pharmaceutical companies .
- AstraZeneca plc - Part of the composite peer group of major U.S. and European-based pharmaceutical companies .
- Bristol-Myers Squibb Company - Part of the composite peer group of major U.S. and European-based pharmaceutical companies .
- Johnson & Johnson - Part of the composite peer group of major U.S. and European-based pharmaceutical companies .
- Eli Lilly and Company - Part of the composite peer group of major U.S. and European-based pharmaceutical companies .
- Gilead Sciences Inc. - Part of the composite peer group of major U.S. and European-based pharmaceutical companies .
- GlaxoSmithKline plc - Part of the composite peer group of major U.S. and European-based pharmaceutical companies .
- Novartis AG - Part of the composite peer group of major U.S. and European-based pharmaceutical companies .
- Pfizer Inc. - Part of the composite peer group of major U.S. and European-based pharmaceutical companies .
- Roche Holding AG - Part of the composite peer group of major U.S. and European-based pharmaceutical companies .
- Sanofi SA - Part of the composite peer group of major U.S. and European-based pharmaceutical companies .
Customer | Relationship | Segment | Details |
---|---|---|---|
McKesson Corporation | Major drug wholesaler & distributor | All | 21% of total accounts receivable |
Cencora, Inc. | Major drug wholesaler & distributor | All | 20% of total accounts receivable |
Cardinal Health, Inc. | Major drug wholesaler & distributor | All | 14% of total accounts receivable |
Recent developments and announcements about MRK.
Corporate Leadership
Board Change
Surendralal L. 'Lal' Karsanbhai has been elected to the Merck Board of Directors, effective January 1, 2025. He will also serve on the Audit and Governance Committees. Mr. Karsanbhai is currently the President and CEO of Emerson Electric Co. and will stand for election by Merck's shareholders in May 2025. With his addition, the board will consist of 13 members .